Trem2 Variants In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Trem2 Variants In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variants are significant genetic risk factors for late-onset Alzheimer's disease, implicating microglia-mediated immune responses in AD pathogenesis.
- Gene: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
- Chromosome: 6p21.1
- Inheritance: Autosomal dominant (incomplete penetrance)
- Risk Variants: ~10 coding variants associated with AD risk
- Population Frequency: ~0.1-0.3% for risk variants
- Type: Single-pass transmembrane protein
- Extracellular: Ig-like V-type domain
- Ligands: Aβ, lipids, lipoproteins, apoptotic cells
- Signaling: Associates with DAP12 (TYROBP) for signal transduction
| Function |
Description |
| Phagocytosis |
Clears Aβ plaques, cellular debris |
| Survival |
Promotes microglial survival |
| Proliferation |
Supports microglial expansion |
| Cytokine production |
Regulates inflammatory responses |
| Lipid metabolism |
Processes lipids and lipoproteins |
Aβ/Lipids → TREM2 → DAP12 (ITAM) → SYK → PI3K/AKT, MAPK
↓
Proliferation, Survival, Phagocytosis
- Risk: 2-4x increased AD risk
- Effect: Impaired ligand binding
- Frequency: ~0.2% (Caucasian)
- Function: Severely reduced phagocytosis of Aβ
- Reference: Guerreiro et al., 2013
- Risk: 1.5-2x increased AD risk
- Effect: Reduced TREM2 function
- Frequency: ~0.3%
- Function: Mildly impaired signaling
- Reference: Guerreiro et al., 2013
- Risk: ~2x increased AD risk
- Effect: Altered protein function
- Reference: Jin et al., 2014
- Actually a risk variant; no known protective TREM2 variants in AD
- Rare protective variants in other neurodegenerative diseases
Many AD-risk variants cause partial loss of function:
- Reduced ligand binding: Cannot effectively bind Aβ/lipids
- Impaired signaling: Reduced downstream activation
- Decreased phagocytosis: Accumulation of Aβ plaques
- Microglial dysfunction: Failed response to neurodegeneration
TREM2 risk variants impair microglial functions:
| Function |
Normal |
Risk Variant |
| Aβ clearance |
Efficient |
Reduced |
| Plaque containment |
Forms barrier |
Fails containment |
| Survival under stress |
Robust |
Compromised |
| Cytokine regulation |
Balanced |
Dysregulated |
- Plaque burden: Increased in TREM2 risk carriers
- Plaque morphology: Diffuse plaques, less compact
- Spatial distribution: More widespread deposition
- Vascular involvement: Can affect CAA
- Interaction: TREM2 variants may influence tau progression
- Mechanism: Microglial-mediated neuronal injury
- Evidence: Mixed findings in human studies
- Chronic activation: Paradoxically, TREM2 deficiency reduces inflammation
- Beneficial vs harmful: Context-dependent effects
- Therapeutic window: Agonists may restore function
- Effect: Earlier onset by ~2-4 years in homozygotes
- Variable: Modest effect compared to APOE4
- More rapid: Faster progression reported in some studies
- Biomarker changes: Altered CSF sTREM2 levels
- Amyloid PET: Increased cortical amyloid
- FDG-PET: Reduced metabolism in affected regions
- MRI: Hippocampal atrophy
- Source: Proteolytic cleavage of TREM2
- CSF levels: Increased in early AD
- Variant effects: Different sTREM2 patterns
- Reference: Suarez-Calvet et al., 2016
- Risk assessment: Informational use only
- Not deterministic: Similar to APOE
- Counseling: Important for interpretation
- Activate TREM2 signaling
- Restore microglial function
- Enhance Aβ clearance
| Drug |
Company |
Status |
| AL002 |
Alector/GSK |
Phase 2 |
| AL003 |
Alector |
Preclinical |
| PRT-A |
Promising |
Research |
- Rationale: TREM2 agonists may enhance anti-Aβ therapy efficacy
- Rationale: Improve microglial clearance of cleared plaques
- Approach: Deliver functional TREM2
- Challenge: Achieving microglial expression
Trem2 Variants In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Trem2 Variants In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Guerreiro R, et al. (2013). TREM2 variants in Alzheimer's disease. New England Journal of Medicine.
- Jonsson T, et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. New England Journal of Medicine.
- Ulrich JD, et al. (2017). Elucidating the Role of TREM2 in Alzheimer's Disease. Neuron.
- Song W, et al. (2018). TREM2 in neurodegeneration: evidence for mechanisms of protective microglial function. Science Advances.
- Chen X, et al. (2020). TREM2 Agonism as a Therapeutic Target in Alzheimer's Disease. Journal of Neuroinflammation.